An FDA panel recommended the approval of Johnson & Johnson's Invokana, or canagliflozin to treat type 2 diabetes in a 10-5 vote. Some advisers suggested that patients with impaired kidneys should be told not to take the drug.
FDA advisers endorse J&J's canagliflozin for diabetes
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|